Drug Trial Radar · NCT06321913
Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
25
Planned (sponsor's estimate)
Start
Mar 15, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Harbin Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial\] is toevaluate the safety, tolerability and efficacy of IBI343 combined with sintilimab in the treatment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma. The main aim is to evaluate the efficacy and safety of IBI343 combination treatment in subjects with advanced gastric/gastroesophageal junction adenocarcinoma.The secondary aim is to evaluate other efficacy endpoints in subjects with IBI343 combination therapy for advanced gastric/gastroesophageal junction adenocarcinoma.The exploratory purpose is to evaluate the correlation between CLDN18.2 expression levels in tumor tissues and the efficacy of IBI343 combination therapy. Participants will be asked to enroll about 3-12 patients in the safety introduction period.,and about 25 patients are planned to be enrolled in the POC phase.
Conditions
- Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
IBI343 combined with IBI308Drug
IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 24 months
- AETime frame: 24 months
- Treatment-Emergent Adverse Event (TEAE)Time frame: 24 months
- Adverse Event of Special Interest (AESI)Time frame: 24 months
- Serious Adverse Event (SAE)Time frame: 24 months
- laboratory examinationsTime frame: 24 months
- physical examinationsTime frame: 24 months
- vital signsTime frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.